Fundraising Fox

Maha Radhakrishnan

Investor

Executive Partner, Private Equity at Sofinnova Ventures

About

Maha Radhakrishnan is an industry executive with decades of experience in product development, commercialization, and global medical strategy across biotechnology and pharmaceutical companies. Before joining Sofinnova in 2024, she served as Consultant to the CEO at Dyne Therapeutics, Chief Medical Officer at Biogen, and Senior Vice President and Global Head of Medical for the Primary Care Business Unit at Sanofi, with earlier leadership roles at Bioverativ, Bristol Myers Squibb, United Health Group, and Cephalon. She holds an M.D. in internal medicine from the People's Friendship University in Moscow and a master's degree in Russian language.

Invests in

Biotech

Investments

Per the firm's website.

Colleagues at Sofinnova Ventures

Frequently asked questions

Who is Maha Radhakrishnan?
Maha Radhakrishnan is an industry executive with decades of experience in product development, commercialization, and global medical strategy across biotechnology and pharmaceutical companies. Before joining Sofinnova in 2024, she served as Consultant to the CEO at Dyne Therapeutics, Chief Medical Officer at Biogen, and Senior Vice President and Global Head of Medical for the Primary Care Business Unit at Sanofi, with earlier leadership roles at Bioverativ, Bristol Myers Squibb, United Health Group, and Cephalon. She holds an M.D. in internal medicine from the People's Friendship University in Moscow and a master's degree in Russian language.
Where does Maha Radhakrishnan work?
Maha Radhakrishnan is Executive Partner, Private Equity at Sofinnova Ventures.
What does Maha Radhakrishnan invest in?
Maha Radhakrishnan invests in Biotech.
What boards does Maha Radhakrishnan sit on?
Maha Radhakrishnan holds tracked board seats at City Therapeutics.